Latest Updates & Insights
News
Trace the advancements of Allorion Therapeutics through the years
News sorted by year
2025
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor
2024
January 4, 2024
Avenzo Therapeutics announces global license of AVZO-021 (ARTS-021), a potentially best-in-class clinical stage CDK2 inhibitor from Allorion Therapeutics
January 2, 2024
Allorion Therapeutics announces exclusive option and global license agreement for novel preclinical-stage EGFR L858R allosteric inhibitor program with AstraZeneca
2023
October 17, 2023
Allorion Therapeutics presents at the ESMO Conference 2023
Allorion Therapeutics, a clinical-stage biotechnology company that develops novel small molecule drugs for cancer and autoimmune diseases, today announced that one abstract has been selected for poster presentation at the ESMO Conference, taking place from October 20-24, 2023, in Madrid, Spain.
Poster title: ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
October 11, 2023
Allorion Therapeutics presents preclinical data supporting the development of its CDK2 inhibitor at the AACR-NCI-EORTC International Conference 2023
The preclinical data for ARTS-021 will be presented on October 12 and 13 in the poster sessions at the AACR-NCI-EORTC International Conference 2023 in Boston, Massachusetts.
October 5, 2023
Allorion Therapeutics announces first patient dosed in phase1/2 study of ARTS-021, a potential best in class CDK2 inhibitor, for advanced or metastatic solid tumors
May 26, 2023
Allorion Therapeutics announces FDA clearance of IND application for ARTS-021
Allorion Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ARTS-021, a CDK2 inhibitor that targets CCNE1-amplified cancers and HR+/HER2- breast cancers. ARTS-021 is a highly selective isoform-specific drug that aims to improve efficacy and overcome resistance in these hard-to-treat cancers.
April 6, 2023
Allorion Therapeutics announces CDE clearance of IND application for ARTS-011
Allorion Therapeutics today announced that the China Center for Drug Evaluation (CDE) has cleared the Company’s Investigational New Drug (IND) application for ARTS-011, a highly selective TYK2 allosteric inhibitor. The Company aims to treat various autoimmune diseases with this novel drug candidate.
April 3, 2023
Allorion Therapeutics appoints Dr. Gregory Berk as Chief Medical Officer
Allorion Therapeutics today announced the appointment of Gregory Berk, M.D. as the Company’s Chief Medical Officer.
March 9, 2023
Allorion Therapeutics announces $50 million series B financing
Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced the completion of $50M Series B financing.
2022
May 6, 2022
Allorion Therapeutics presents preclinical data supporting the development of its TYK2 inhibitor at the IMMUNOLOGY2022 meeting
Allorion Therapeutics named ARTS-011 as the development candidate for its TYK2 program. The preclinical data for ARTS-011 will be presented on May 7 in a poster session at the American Association of Immunologists (AAI) Annual Meeting 2022 in Portland, Oregon.
April 8, 2022
Allorion Therapeutics presents preclinical data supporting the development of its CDK2 inhibitor at the AACR Annual Meeting 2022
Allorion Therapeutics named ARTS-021 as the development candidate for its CDK2 program. The preclinical data for ARTS-021 will be presented on April 12 in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, Louisiana.
2021
ENDPOINTS NEWS | November 23, 2021
A fledgling transpacific biotech grabs a launch round to dive into oncology and autoimmune research
Precision-med biotech Allorion Therapeutics is expanding — and now has tens of millions of dollars more to work with.
November 23, 2021
Allorion Therapeutics announces $40 million series A financing
Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, today announced the completion of $40M Series A financing.
2020
December 1, 2020
Allorion Therapeutics builds internal laboratories
Allorion Therapeutics established laboratories at our Natick and Guangzhou sites and put them into operation, enabling us to carry out biological and chemical experiments in-house. Together with our contract research organizations, these internal experimental facilities will further strengthen our R&D capabilities.
